Is There a Role for Adjuvant High-Dose Interferon- -2b in the Management of Melanoma?

ISSN： 0012-6667

Source： Drugs, Vol.63, Iss.11, 2003-01, pp. : 1053-1058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High-dose IFN- -2b improves survival in melanoma?

Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Sargramostim: potential adjuvant therapy in melanoma?

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

HLA expression predicts IFN- -2b response in melanoma?

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

By Chapman Paul B.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 1, 2004-01 ,pp. : 69-72

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Early, high-dose thyroxine benefits neonates with CH?

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite